This strategy has already been included in iPSC-derived CAR-NK cells targeting B-cell maturation antigen (BCMA) in MM (FT576 NK cells) (74, 75) or targeting CD19 in B-cell malignancies (FT596 NK cells) (Fate Therapeutics) (76). This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.